In another mouse study, the timing of 20 Gy × 1 fraction and anti-CTLA4 antibodies reported that the best tumor control and survival advantage was observed in the group that started the anti-CTLA4 antibodies before radiotherapy, compared with the group that started it after radiotherapy (69). The gene discussed is CTLA4; the disease is neoplasm.